BREVENAIR

Brevenair was founded by Dan, after his UNCW retirement in 2019. He is internationally recognized for his R&D of the biopharmaceuticals produced by Karenia brevis. His work includes 16 new bioactives, RIA, ELISA, antibodies, receptor binding assays, photoaffinity and fluorescent probes. Funded by NIH 1979-2019, he has focused on ion channel diseases, therapeutic targets, and translational research. The WB53 variant is personally owned by Professor Baden and he has licensed it globally for all fields of use to Brevenair, Inc. Despite the original patents on Brevenal for CF having expired, Vertex owns the majority of the market share. Meanwhile, the Company has proven proprietary technologies and methodologies along with more recent patent filings for unique derivatives of the Breven family of LFPs... Brevenair, Inc. is focused on commercializing drug candidates for a special class of Ladder Frame Polyethers (LFPs). Our patent-pending New Chemical Entities (NCEs) could be the basis for..

Also known as: Brevenair, Inc.